Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market

Fineline Cube Mar 13, 2026
Company Deals

APC Group and Youcare Pharmaceutical Forge Strategic Partnership – Global Distribution Alliance Targets China-India Pharma Collaboratio

Fineline Cube Mar 13, 2026
Company Deals

WuXi Biologics Partners with Earendil Labs – Integrated CDMO Services for Bispecific Antibodies and ADCs Targeting Autoimmune and Oncology Indications

Fineline Cube Mar 13, 2026
Company Deals

Everest Medicines Reports Positive Phase IIa Data for VIS-101 – Dual VEGF-A/Ang-2 Inhibitor Shows Best-in-Class Potential in wAMD

Fineline Cube Mar 13, 2026
Company Deals

Luye Pharma Signs Strategic Partnership with Sinopharm – Mimeixin Distribution Deal Targets China’s Severe Pain Market

Fineline Cube Mar 13, 2026
Policy / Regulatory

FDA Streamlines Biosimilar Development – New Guidance Cuts PK Study Costs by 50%, Accelerates Path to Market

Fineline Cube Mar 10, 2026
Company Drug

Sino Biopharm’s TQB3454 Hits Phase III Endpoints in IDH1+ Biliary Tract Cancer – China’s First IDH1 Inhibitor Poised for NDA Filing

Fineline Cube Mar 13, 2026
Company Drug

CMS Launches Opzelura Nationwide – First Topical JAK Inhibitor for Vitiligo Reaches 1,300+ Pharmacies Across 30 Chinese Provinces

Fineline Cube Mar 13, 2026
Company Drug

BeiGene’s Tislelizumab Meets Primary Endpoint in HCC Study at ESMO

Fineline Cube Sep 13, 2022

BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) presented the latest results of the global Phase...

Company Drug

Luye Pharma’s BA-CovMab Receives NMPA Approval for COVID-19 Clinical Trials

Fineline Cube Sep 13, 2022

China-based Luye Pharma Group (HKG: 2186) announced that its subsidiary Shandong BoAn Biotechnology Co., Ltd’s...

Policy / Regulatory

Jiangsu Healthcare to Cover All Psychological Treatments Under BMI

Fineline Cube Sep 13, 2022

The Jiangsu Provincial Healthcare Security Administration is reportedly considering adding all psychological diagnosis and treatment...

Company Deals

Leadinno Medical Valley Raises RMB 100M in Series A Financing for Neuromodulation Devices

Fineline Cube Sep 13, 2022

Beijing-based neuromodulation medical device maker Leadinno Medical Valley reportedly raised over RMB 100 million (USD...

Company Drug

Transcenta’s TST001 Shows Promise in Gastric Cancer Trial with 73.3% Response Rate

Fineline Cube Sep 13, 2022

China-based biotech Transcenta Holdings Ltd (HKG: 6628) announced interim safety and efficacy data from a...

Company Drug

CSPC Pharmaceutical’s TG103 Gains NMPA Approval for NASH and Alzheimer’s Trials

Fineline Cube Sep 13, 2022

China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) announced that it has received approval from...

Company Drug

Jingxin Pharmaceutical Receives NMPA Approval for JBPOS0101 and JX7002 Trials

Fineline Cube Sep 13, 2022

Jingxin Pharmaceutical Co., Ltd (SHE: 002020) announced that it has received clinical trial approvals from...

Drug

China’s Retail Pharmacy O2O Sales Surge to USD 2.9B in 2021

Fineline Cube Sep 9, 2022

According to the “China Retail Pharmacy O2O Development Report” released by Minenet, the “online drug...

Medical Device Policy / Regulatory

National High-Value Medical Consumables VBP Round Targets Orthopedic Spine Products

Fineline Cube Sep 9, 2022

The national high-value medical consumables joint procurement office released a set of guiding opinions on...

Company Drug

China’s Cecolin HPV Vaccine Shows 100% Efficacy in 66-Month Study

Fineline Cube Sep 9, 2022

Chinese researchers have published 66-month follow-up data from a Phase III clinical study for the...

Company Drug

Dizal Pharma’s Sunvozertinib Gains NMPA Approval for EGFR Mutation NSCLC Trial

Fineline Cube Sep 9, 2022

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced that it has received clinical trial approval...

Company Policy / Regulatory

MofCOM’s 2021 Pharma Distribution Report Shows Market Recovery

Fineline Cube Sep 9, 2022

The Ministry of Commerce (MofCOM) released its annual statistical review of the pharma distribution industry...

Policy / Regulatory

NHSA Issues Notice on Special Treatment of Oral Implant Medical Service Charges

Fineline Cube Sep 9, 2022

The National Healthcare Security Administration (NHSA) has released a Notice on “Carrying out Special Treatment...

Company Drug

Keymed and Lepu’s CMG901 Receives Breakthrough Therapy Designation for Gastric Cancer

Fineline Cube Sep 9, 2022

The Center for Drug Evaluation (CDE) website indicates that CMG901, a Claudin 18.2 (CLDN18.2)-targeted antibody...

Company Deals Digital

Realcan Pharma and AWS Expand Partnership for Digital Transformation

Fineline Cube Sep 9, 2022

China-based Realcan Pharmaceutical Group Co., Ltd (SHE: 002589) and Amazon Web Services (AWS) have agreed...

Company Legal / IP

Salipro Biotech Secures Patent Protection for Membrane Protein Stabilization Tech

Fineline Cube Sep 9, 2022

Sweden-based Salipro Biotech AB announced that its core technology for stabilizing membrane proteins for drug...

Company Drug

Sirnaomics Initiates Phase I Study of STP705 for Abdominal Fat Reduction

Fineline Cube Sep 8, 2022

Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced the first subject dosing in...

Company

China Pharma H1 2022 Financials: 40% of Firms Report Revenue and Profit Growth

Fineline Cube Sep 8, 2022

A total of 449 pharmaceutical and health-tech companies listed in China have released their H1...

Company Deals

Suzhou InnoBM Pharmaceuticals Raises Series A+ Funding for Tumor Immunotherapy

Fineline Cube Sep 8, 2022

China-based Suzhou InnoBM Pharmaceuticals reportedly raised tens of millions of renminbi in a Series A+...

Company Drug

Laekna Therapeutics Doses First Patient in LAE001/LAE002 Study for Prostate Cancer

Fineline Cube Sep 8, 2022

China-based Laekna Therapeutics Shanghai Co., Ltd announced that the first patient has been dosed in...

Posts pagination

1 … 594 595 596 … 634

Recent updates

  • Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market
  • Sino Biopharm’s TQB3454 Hits Phase III Endpoints in IDH1+ Biliary Tract Cancer – China’s First IDH1 Inhibitor Poised for NDA Filing
  • CMS Launches Opzelura Nationwide – First Topical JAK Inhibitor for Vitiligo Reaches 1,300+ Pharmacies Across 30 Chinese Provinces
  • Essight Bio’s ES502 Wins FDA Phase I Approval – First TCR×CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic
  • APC Group and Youcare Pharmaceutical Forge Strategic Partnership – Global Distribution Alliance Targets China-India Pharma Collaboratio
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market

Company Drug

Sino Biopharm’s TQB3454 Hits Phase III Endpoints in IDH1+ Biliary Tract Cancer – China’s First IDH1 Inhibitor Poised for NDA Filing

Company Drug

CMS Launches Opzelura Nationwide – First Topical JAK Inhibitor for Vitiligo Reaches 1,300+ Pharmacies Across 30 Chinese Provinces

Company Drug

Essight Bio’s ES502 Wins FDA Phase I Approval – First TCR×CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.